Remove Licensing Remove Life Science Remove Pharma Companies Remove Regulation
article thumbnail

4 Life Sciences Trends for 2023

XTalks

The life sciences and healthcare are among the biggest industries globally, and their significance was particularly highlighted during the past couple of years by the COVID-19 pandemic. Given the hyperfocus on the life sciences thanks to COVID, consumers appear to be more autonomous and vocal about their medical demands and choices.

article thumbnail

Europe: Where is the drug discovery innovation?

Drug Discovery World

Thanks to a prestigious academic legacy, Europe has long been a dominant region for life sciences. Europe is traditionally a life sciences powerhouse, with a strong tradition in pharmaceutical discovery. The oldest, still active pharmaceutical company worldwide, Merck, started life in 1668 in Darmstadt, Germany.

Drugs 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Veeva Systems Summit, Madrid – pharmaphorum reflects

pharmaphorum

Veeva Systems invited pharmaphorum to attend its industry summit in Madrid this week, a huge event that gathered together over 1,000 individuals from life sciences and pharma. The question is, how can the journey there be accelerated, when on the horizon awaits a life sciences future very much immersed in speciality medicine?

article thumbnail

The Pandemic Treaty and the opportunity to end ‘vaccine apartheid’

pharmaphorum

There are already rules that dictate how countries should react against public health events that have the potential to traverse country borders, through the International Health Regulations. The industry has so far resisted demands for the sharing of intellectual property (IP) around products developed to counter the pandemic.

article thumbnail

Can technology help diversify clinical trials?

pharmaphorum

Once stakeholders are confident that technologies are adequately validated, selection based on scientific and ethical considerations can be presented to regulators in accordance with applicable legal and regulatory frameworks. There is a huge opportunity for pharma companies to capitalise on by focusing on increased DEI in clinical trials.

article thumbnail

The Brexit deal; shot in the arm or kick in the teeth for the pharma sector?

pharmaphorum

The UK Government and EU Commission trumpeted their Brexit trade deal, struck at the end of December, as ‘comprehensive’, the ‘biggest yet’ But a closer inspection of the EU-UK Trade and Cooperation Agreement (TCA) renders these statements largely illusory for the pharma sector. Andrew is also an expert on GDPR.

article thumbnail

How will NICE fare in a post-Brexit world?

pharmaphorum

Long headquartered in London, the EU drug regulator is now severed from the country both physically and systematically, with its base now in Amsterdam and the UK now assessing drugs through its own regulatory agency, MHRA.